Enigma Biomedical - USA Partners with Alamar Biosciences to Advance the Diagnostics for Neurodegenerative Diseases
Shots:
- Enigma Biomedical USA and Alamar Biosciences have partnered under which EB gains non-exclusive rights to introduce Alamar's ARGO HT instrument and NULISA reagent kits to academic and pharma customers in neurology research
- The partnership aims to generate a large data set from neuroimaging & immunoassays, leading to more effective diagnostic solutions for patient-specific therapies
- Enigma Biointelligence (EBI), an affiliate of EB, will allow users to order Alamar’s immunoassays via EBI’s Minerva Bio Platform. EBI’s Health Grid will help academic and pharma sponsors manage and interpret study data, incl. data from EB’s PET tracers and NULISA tests. EB and Alamar plan to develop analytics products from shared customer data
Ref: Businesswire | Image: Enigma Biomedical & Alamar Biosciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
